Arrow Greentech Ltd

₹ 889 -1.47%

18 Sep - close price

arrowgreentech.com BSE: 516064 NSE: ARROWGREEN

About

Incorporated in 1982, Arrow Greentech
Ltd is in the business of bio-degradable (green) products, high-tech products and having Patents income for such products /technology^[1]

Key Points

Business Overview:^[1]^[2]
AGL is India’s largest manufacturer of water-soluble films, specializing in the development, production, and marketing of a diverse range of PVA/PVOH-based films. Its portfolio includes innovative applications such as mouth dissolving strips for pharmaceutical and nutraceutical use. In addition to green packaging solutions, AGL also offers advanced security products and intellectual property services, positioning itself as a multi-vertical technology-driven company.

Website BSE NSE

Market Cap ₹ 1,342 Cr.
Current Price ₹ 889
High / Low ₹ 953 / 342
Stock P/E 22.6
Book Value ₹ 147
Dividend Yield 0.56 %
ROCE 27.6 %
ROE 19.7 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company is almost debt free.
Company is expected to give good quarter
Company has delivered good profit growth of 74.4% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 30.0%
Promoter holding has increased by 0.82% over last quarter.
Company's median sales growth is 18.6% of last 10 years

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Industrials Capital Goods Industrial Products Packaging

Part of BSE Industrials

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	31	29	25	48	64	57	40	39	33	45	45	34	77
	18	18	16	28	35	31	26	26	21	28	28	24	43
Operating Profit	12	11	9	20	29	26	15	13	12	17	17	10	34
OPM %	40%	37%	36%	42%	45%	46%	36%	33%	36%	38%	37%	29%	44%
	1	1	1	2	1	1	1	2	2	2	2	2	2
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	1	1	1	1	1	1	1	1	1	1	1	1	1
Profit before tax	12	11	9	21	29	26	15	13	12	18	17	11	35
Tax %	30%	28%	18%	23%	26%	26%	26%	22%	25%	24%	31%	26%	25%
	9	8	7	16	21	20	11	10	9	13	12	8	26
EPS in Rs	5.79	5.04	4.69	10.53	14.07	12.94	7.16	6.84	6.09	8.88	7.90	5.29	17.29
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	20	23	31	39	43	31	27	24	106	132	201	157	201
	11	11	15	27	46	28	23	29	78	80	118	101	123
Operating Profit	9	12	16	12	-3	4	3	-5	28	52	83	56	78
OPM %	46%	51%	52%	31%	-7%	12%	13%	-22%	26%	39%	41%	36%	39%
	1	5	2	10	7	2	3	7	4	6	5	8	8
Interest	0	0	0	0	0	1	1	1	1	0	0	1	0
Depreciation	1	1	1	4	3	3	4	4	4	5	5	5	5
Profit before tax	9	16	17	18	1	2	2	-3	27	52	83	58	81
Tax %	30%	29%	18%	16%	81%	7%	-57%	-43%	29%	25%	25%	27%
	7	11	14	15	0	2	3	-2	19	39	62	42	59
EPS in Rs	4.65	7.96	9.79	10.74	0.13	1.50	1.79	-1.21	12.51	26.05	41.03	28.16	39.36
Dividend Payout %	45%	47%	48%	16%	309%	0%	0%	0%	8%	8%	10%	18%

Compounded Sales Growth
10 Years:	21%
5 Years:	42%
3 Years:	14%
TTM:	19%

Compounded Profit Growth
10 Years:	14%
5 Years:	74%
3 Years:	28%
TTM:	19%

Stock Price CAGR
10 Years:	7%
5 Years:	50%
3 Years:	38%
1 Year:	56%

Return on Equity
10 Years:	23%
5 Years:	26%
3 Years:	30%
Last Year:	20%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	12	12	12	12	12	14	14	14	15	15	15	15
Reserves	10	16	30	38	36	44	46	44	73	111	170	206
	0	0	0	0	0	5	4	4	3	0	0	2
	9	6	6	6	7	7	7	7	15	10	12	11
Total Liabilities	31	33	47	56	55	70	71	69	106	136	196	234
	5	5	16	16	13	17	15	14	12	15	17	17
CWIP	1	1	1	1	1	0	0	1	1	3	2	1
Investments	15	16	19	26	12	11	6	2	1	37	82	113
	9	11	11	14	28	42	50	52	92	81	95	103
Total Assets	31	33	47	56	55	70	71	69	106	136	196	234

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	10	7	12	3	-10	10	-0	1	10	20	66	29
	-11	3	-12	1	14	-23	-0	0	-18	-16	-58	-27
	-2	-7	-2	-6	-2	12	-1	-1	9	-4	-4	-7
Net Cash Flow	-3	3	-2	-2	2	-0	-2	0	0	-1	5	-4
Free Cash Flow	6	8	1	1	-11	1	-2	-3	7	9	60	27
CFO/OP	123%	119%	95%	55%	305%	295%	13%	-30%	45%	67%	107%	80%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	9	9	21	29	59	31	91	42	72	67	43	72
Inventory Days	72	155	225	200	77	92	136	215	103	155	85	125
Days Payable	171	182	238	101	43	74	71	107	59	19	24	23
Cash Conversion Cycle	-90	-19	8	128	93	48	156	150	116	203	103	174
Working Capital Days	-102	-35	8	60	83	16	74	63	76	115	65	108
ROCE %	46%	64%	48%	39%	2%	6%	4%	-4%	36%	49%	53%	28%

Insights

In beta

Mar 2016

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Granted Patents (In-force)
count

xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
						xx	xx	xx	xx
						xx	xx	xx	xx
						xx	xx	xx	xx
						xx	xx	xx	xx

Please log in to see hidden values.

Avery Pharma FSSAI Approved Products
count

Avery Pharma RX (Prescription) Approved Products
count

Patent Applications in Process (Total)
count

Registered Trademarks
count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	68.60%	68.60%	68.60%	68.60%	66.75%	64.81%	64.81%	64.81%	64.81%	64.81%	64.83%	65.65%
	0.02%	0.00%	1.28%	0.21%	0.09%	0.56%	0.27%	0.25%	0.12%	0.14%	0.06%	0.20%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.04%	0.11%	0.69%	0.79%	0.82%	0.99%
	31.38%	31.42%	30.13%	31.19%	33.16%	34.63%	34.88%	34.84%	34.38%	34.25%	34.28%	33.16%
No. of Shareholders	8,137	12,630	13,430	14,838	22,320	22,038	22,605	21,685	21,947	21,521	21,442	20,487

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Jun 2026
	69.68%	65.42%	65.42%	70.35%	70.28%	70.35%	68.60%	68.60%	64.81%	64.83%	65.65%
	0.80%	1.30%	0.83%	0.10%	0.21%	0.00%	0.13%	1.28%	0.27%	0.06%	0.20%
	0.35%	8.16%	1.95%	0.14%	0.00%	0.00%	0.00%	0.00%	0.04%	0.82%	0.99%
	29.18%	25.12%	31.80%	29.41%	29.52%	29.65%	31.28%	30.13%	34.88%	34.28%	33.16%
No. of Shareholders	5,981	8,578	9,402	8,595	7,638	8,934	7,760	13,430	22,605	21,442	20,487

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Right Issue

Concalls

Aug 2026

Transcript

AI Summary
PPT
May 2026

Transcript

AI Summary
PPT
Feb 2026

Transcript

AI Summary
PPT
Nov 2025

Transcript

AI Summary
PPT
Aug 2025

Transcript

AI Summary
PPT
May 2025

Transcript

AI Summary
PPT
Feb 2025

Transcript

AI Summary
PPT
Oct 2024

Transcript

AI Summary
PPT
May 2024

Transcript

AI Summary
PPT
May 2024

Transcript

AI Summary
PPT
May 2024

Transcript

AI Summary
PPT
Feb 2024

Transcript

AI Summary
PPT
Nov 2023

Transcript

AI Summary
PPT
Jun 2023

Transcript

AI Summary
PPT
Nov 2019

Transcript

AI Summary
PPT
Feb 2019

Transcript

AI Summary
PPT
Aug 2016

Transcript

AI Summary
PPT
May 2016

Transcript

AI Summary
PPT
Nov 2015

Transcript

AI Summary
PPT
Aug 2015

Transcript

AI Summary
PPT